Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: Inhibition of platinum-DNA adduct removal

Clinical Cancer Research

Volumn 3, Issue 5, 1997, Pages 761-770

  Adjei, Alex A ^a,b   Budihardjo, I Imawati ^b   Rowinsky, Eric K ^a   Kottke, Timothy J ^b   Svingen, Phyllis A ^b   Buckwalter, Christopher A ^b   Grochow, Louise B ^a   Donehower, Ross C ^a   Kaufmann, Scott H ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; APHIDICOLIN; CISPLATIN; CYTARABINE; FLUOROURACIL; METHOTREXATE; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIC CELL; LUNG NON SMALL CELL CANCER; MICROFLUOROMETRY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ACRIDINES; ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHO CELLS; CISPLATIN; CRICETINAE; DNA ADDUCTS; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; INTERCALATING AGENTS; INTESTINAL NEOPLASMS; PYRAZOLES; TUMOR CELLS, CULTURED;

EID: 0030970983     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Sebolt, J., Scavone, S., and Pinter, C. Pyrazoloacridines: a new class of antitumor agents with selectivity against solid tumors in vitro. Cancer Res., 47: 4299-4304, 1987.
2. Adjei, A. A., Charron, M., Rowinsky, E. K., Donehower, R. C., Sebolt-Leopold, J., and Kaufmann, S. H. Pyrazoloacridine inhibits DNA topoisomerases I and II. Proc. Am. Assoc. Cancer Res., 36: 349, 1995.
3. LoRusso, P., Wozniak, A. J., and Polin, L. Antitumor efficacy of PD115932 (NSC 366140) against solid tumors of mice. Cancer Res., 50: 4900-4905, 1990.
4. Jackson, R., Sebolt, J., and Shillis, J. The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest., 8: 39-47, 1990.
5. Sebolt, J., Havlick, M., and Hamelehle, K. Activity of the pyrazoloacridines against multidrug-resistant Tumor cells. Cancer Chemother. Pharmacol., 24: 219-224, 1989.
6. Cole, S. P. C. Patterns of cross-resistance in a multidrug-resistant small cell lung carcinoma line. Cancer Chemother. Pharmacol., 26: 250-256, 1990.
7. LoRusso, P., Foster, B. J., Poplin, E., McCormick, J., Kraut, M., Flaherty, L., Heilbrun, L. K., Valdivieso, M., and Baker, L. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin. Cancer Res., 1: 1487-1493, 1995.
8. Rowinsky, E. K., Noe, D. A., Grochow, L. B., Sartorious, S. E., Bowling, M. K., Chen, T-L., Lubejko, B. G., Kaufmann, S. H., and Donehower, R. C. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single and multiple dosing schedules. J. Clin. Oncol., 13: 1975-1984, 1995.
9. Ozols, R. F. Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma. Ann. Oncol., 5 (Suppl. 6): S39-S43, 1994.
10. McGuire, W. P., Joskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
11. Ozols, R. F. USA: update on paclitaxel in ovarian cancer. Ann. Med., 27: 127-130, 1995.
12. Reed, E., Kohn, E. C., Sarosy, G., Dabholkar, M., Davis, P., Jacob, J., and Maher, M. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer. Molecular rationale and early clinical results Semin Oncol., 22 (3 Suppl. 6): 90-96, 1995.
13. Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., and Kaufmann, S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res., 52: 2268-2278, 1992.
14. Chou, T.-C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
15. Johnson, S. W., Perez, R. P., Godwin, A. K., Yeung, A. T., Handel, L. M., Ozols, R. F., and Hamilton, T. C. Role of platinum-DNA adduct formation and removal of cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 47: 689-697, 1994.
16. Bible, K. C., and Kaufmann, S. H. Flavopiridol (NSC 649890, L86-8275): a cytotoxic flavone that induces cell death in human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
17. Armstrong, D. K., Kaufmann, S. H., Ottaviano, Y. L., Furuya, Y., Buckley, J. A., Isaacs, J. T., and Davidson, J. A. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res., 54: 5280-5283, 1994.
18. Spadari, S., Sala, F., and Pedrali-Noy, G. Aphidicolin: a specific inhibitor of nuclear DNA replication in eukaryotes. Trends Biochem. Sci., 7: 29-32, 1982.
19. Greco, W. R., Bravo, G., and Parsons, J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev., 47: 331-385, 1995.
20. Drewinko, B., Patchen, M., Yang, L-Y., and Barlogie, B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res., 41: 2328-2333, 1981.
21. D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
22. 2-checkpoint inhibitor. Clin. Cancer Res., 2: 791-797, 1996.
23. Sorenson, C. M., and Eastman, A. Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair-proficient and -deficient Chinese hamster ovary cells. Cancer Res., 48: 6703-6707, 1988.
24. O'Connor, P. M., and Kohn, K. W. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells. Semin. Cancer Biol., 3: 409-416, 1992.
25. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
26. Wang, Q., Worland, P. J., Clark, J. L., Carlson, B. A., and Sausville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth & Differ., 6: 927-936, 1995.
27. Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., and O'Connor, P. M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 88: 956-965, 1996.
28. Eder, J. P., Chan, V. T-W., Ng, S-W., Rizvi, N. A., Zacharoulis, S., Teicher, B. A., and Schnipper, L. E. DNA topoisomerase IIα expression is associated with alkylating agent resistance. Cancer Res., 55: 6109-6116, 1995.
29. Ali-Osman, F., Berger, M. S., Rajagopal, S., Spence, A., and Livingston, R. B. Topoisomerase II: inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res., 53: 5663-5668, 1993.
30. Goldwasser, F., Valenti, M., Torres, R., Kohn, K. W., and Pommier, Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin. Cancer Res., 2: 687-693, 1996.
31. Vilpo, J. A., Vilpo, L. M., Szymkowski, D. E., O'Donovan, A., and Wood, R. D. An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Mol. Cell. Biol., 15: 290-297, 1995.
32. Sung, P., Bailly, V., Weber, C., Thompson, L. H., Prakash, L., and Prakash, S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature (Lond.), 365: 852-855, 1993.
33. Drapkin, R., Reardon, J. T., Ansari, A., Huang, J. C., Zawel, L., Ahn, K., Sancar, A., and Reinberg, D. Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature (Lond.), 368: 769-772, 1994.
34. Sebolt-Leopold, J. S., and Scavone, S. V. Biochemistry of the interactions between DNA and the pyrazoloacridines: a series of biologically novel anticancer agents. Proc. Am. Assoc. Cancer Res., 32: 334, 1991.
35. Bachur, N. J., Yu, F., Johnson, R., Hickey, R., Wu, Y., and Malkas, L. Helicase inhibition of anthracycline anticancer agents. Mol. Pharmacol., 41: 993-998, 1992.
36. Skouv, J., Jensen, P. O., Forchhammer, J., Larsen, J. K., and Lund, L. R. Tumor-promoting phorbol ester transiently down-modulates the p53 level and blocks the cell cycle. Cell Growth & Differ., 5: 329-340, 1994.
37. 1 checkpoint-competent cells. Cancer Res., 55: 1639-1642, 1995.
38. Prokocimer, M., Shaklai, M., Ben Bassat, H., Wolf, D., Goldfinger, N., and Rotter, V. Expression of p53 in human leukemia and lymphoma Blood, 68: 113-118, 1986.
39. Patton, T. F., Himmelstein, K. H., and Belt, R. Plasma levels and urinary excretion of filterable platinum species following bolus injection and IV infusion of cis-dichlorodiammineplatinum (II) in man. Cancer Treat. Rep., 62: 1359-1362, 1978.